TrialBlood2022

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.

Matthew M Heeney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.